SciClone Pharmaceuticals (Holdings) (HKSE:06600) EBITDA Margin % : 35.26% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is SciClone Pharmaceuticals (Holdings) EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. SciClone Pharmaceuticals (Holdings)'s EBITDA for the six months ended in Dec. 2023 was HK$599 Mil. SciClone Pharmaceuticals (Holdings)'s Revenue for the six months ended in Dec. 2023 was HK$1,698 Mil. Therefore, SciClone Pharmaceuticals (Holdings)'s EBITDA margin for the quarter that ended in Dec. 2023 was 35.26%.

SciClone Pharmaceuticals (Holdings) EBITDA Margin % Historical Data

The historical data trend for SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SciClone Pharmaceuticals (Holdings) EBITDA Margin % Chart

SciClone Pharmaceuticals (Holdings) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Get a 7-Day Free Trial

40.91

50.04

46.61

40.21

45.03

SciClone Pharmaceuticals (Holdings) Semi-Annual Data
	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial						30.73	40.35	30.72	45.42	35.26

Competitive Comparison of SciClone Pharmaceuticals (Holdings)'s EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, SciClone Pharmaceuticals (Holdings)'s EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % falls into.

SciClone Pharmaceuticals (Holdings) EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	1554.375	/	3451.544
	=	45.03 %

SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	598.701	/	1697.854
	=	35.26 %

SciClone Pharmaceuticals (Holdings) (HKSE:06600) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

SciClone Pharmaceuticals (Holdings) EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of SciClone Pharmaceuticals (Holdings)'s EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SciClone Pharmaceuticals (Holdings) Ltd (HKSE:06600) » Definitions » EBITDA Margin %

Traded in Other Exchanges

N/A

Address

381 Middle Huaihai Road, 22nd Floor, Central Plaza, Shanghai, CHN

Website

https://www.sciclone.com

SciClone Pharmaceuticals (Holdings) Ltd is a biopharmaceutical company with an integrated platform for product development and commercialization. It strategically focuses on some of the fast-growing therapeutic areas with unmet medical needs in China, primarily including oncology and severe infection. It generated revenue primarily from the sale of Zadaxin to Sinopharm.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Zhao Hong	2101 Beneficial owner
Gl Capital Management Gp Limited
Meng Liang	2201 Interest of corporation controlled by you
Ascendent Silver (cayman) Limited	2501 Other
Ascendent Capital Partners Ii Gp Limited	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, Gp, L.p.	2201 Interest of corporation controlled by you
Ascendent Capital Partners Ii, L.p.	2201 Interest of corporation controlled by you
Gl Partners Capital Management Ltd.
Gl China Opportunities Carry Gp Limited
Ocean Falcon Limited	2101 Beneficial owner
Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Bank Of China Limited	2201 Interest of corporation controlled by you
Bank Of China Group Investment Limited	2201 Interest of corporation controlled by you
Gl Capital Management Gp Ii B.c I. Ltd

SciClone Pharmaceuticals (Holdings) (HKSE:06600) Headlines

No Headlines